cyclophosphamide

enUK

cyclophosphamide

[si″klo-fos´fah-mīd] a cytotoxic alkylating agent, one of the nitrogen mustards, used in antineoplastic therapy for a wide variety of conditions, often in combination with other agents; also used as an immunosuppressant to prevent transplant rejection and in the treatment of certain diseases with abnormal immune function.

cyclophosphamide

Endoxana (UK), Procytox (CA)

Pharmacologic class: Alkylating agent, nitrogen mustard

Therapeutic class: Antineoplastic

Pregnancy risk category D

Action

Unclear. Thought to prevent cell division by cross-linking DNA strands, thereby interfering with growth of susceptible cancer cells.

Availability

Powder for injection: 500 mg, 1 g, 2 g

Tablets: 25 mg, 50 mg

Indications and dosages

➣ Hodgkin's disease; malignant lymphoma; multiple myeloma; leukemia; advanced mycosis fungoides; neuroblastoma; ovarian cancer; breast cancer; and certain other tumors

Adults: Initially, 40 to 50 mg/kg I.V. in divided doses over 2 to 5 days, or 10 to 15 mg/kg I.V. q 10 days, or 3 to 5 mg/kg I.V. twice weekly.

Children: Initially, 2 to 8 mg/kg or 60 to 250 mg/m² P.O. or I.V. daily in divided doses for 6 or more days.

Maintenance dosage is 2 to 5 mg/kg or 50 to 150 mg/m² P.O. twice weekly.

➣ Biopsy-proven nephrotic syndrome in children

Children: 2.5 to 3 mg/kg/day P.O. for 60 to 90 days

Off-label uses

• Severe rheumatologic conditions

• Selected cases of severe progressive rheumatoid arthritis and systemic lupus erythematosus

Contraindications

• Hypersensitivity to drug

• Severe bone marrow depression

Precautions

Use cautiously in:

• renal or hepatic impairment, adrenalectomy, mild to moderate bone marrow depression, other chronic debilitating illnesses

• females of childbearing age

• pregnant patients

• breastfeeding patients (use not recommended).

Administration

• Verify that patient isn't pregnant before administering.

• Follow facility procedures for safe handling, administration, and disposal of chemotherapeutic drugs.

• Administer tablets on empty stomach. If drug causes severe GI upset, give with food.

• Don't cut or crush tablets.

• Know that dosage may need to be decreased if drug is given with other antineoplastics.

• Dilute each 100 mg of powder with 5 ml of sterile water for injection, to yield 20 mg/ml. Further dilute with compatible fluid, such as 5% dextrose injection, 5% dextrose and normal saline solution for injection, 5% dextrose and Ringer's injection, lactated Ringer's injection, or half-normal saline solution for injection.

• For I.V. injection, give each 100 mg over at least 1 minute. When giving dosages above 500 mg diluted in 100 to 250 ml of compatible solution, administer over 20 to 60 minutes.

• Use solution prepared with bacteriostatic water for injection within 24 hours if stored at room temperature or within 6 days if refrigerated.

• To minimize bladder toxicity, increase patient's fluid intake during therapy and for 1 to 2 days afterward. Most adults require fluid intake of at least 2 L/day.

Adverse reactions

CV: cardiotoxicity

GI: nausea, vomiting, diarrhea, abdominal pain or discomfort, stomatitis, oral mucosal ulcers, anorexia, hemorrhagic colitis

GU: urinary bladder fibrosis, hematuria, amenorrhea, decreased sperm count, sterility, acute hemorrhagic cystitis, renal tubular necrosis, hemorrhagic ureteral inflammation

Hematologic: anemia, leukopenia, thrombocytopenia, bone marrow depression, neutropenia

Hepatic: jaundice

Metabolic: hyperuricemia

Respiratory: interstitial pulmonary fibrosis

Skin: nail and pigmentation changes, alopecia

Other: poor wound healing, infections, allergic reactions including anaphylaxis, secondary cancer

Interactions

Drug-drug. Allopurinol, thiazide diuretics: increased risk of leukopenia

Digoxin: decreased digoxin blood level

Cardiotoxic drugs (such as cytarabine, daunorubicin, doxorubicin): additive cardiotoxicity

Chloramphenicol: prolonged cyclophosphamide half-life

Phenobarbital: increased risk of cyclophosphamide toxicity

Quinolones: decreased antimicrobial effect

Succinylcholine: prolonged neuromuscular blockade

Warfarin: increased anticoagulant effect

Drug-diagnostic tests. Hemoglobin, platelets, pseudocholinesterase, red blood cells (RBCs), white blood cells: decreased values

Uric acid: increased level

Patient monitoring

• Assess infusion site for signs of extravasation.

• Monitor hematologic profile to determine degree of hematopoietic suppression. Be aware that leukopenia is an expected drug effect and is used to help determine dosage.

• Monitor urine regularly for RBCs, which may precede hemorrhagic cystitis.

Patient teaching

• Tell patient to take tablets on empty stomach. However, if GI upset occurs, instruct him to take them with food.

See Advise patient to promptly report unusual bleeding or bruising, fever, chills, sore throat, cough, shortness of breath, seizures, lack of menstrual flow, unusual lumps or masses, flank or stomach pain, joint pain, mouth or lip sores, or yellowing of skin or eyes.

• Instruct patient to drink 2 to 3 L of fluids daily (unless prescriber has told him to restrict fluids).

• Tell patient that drug may cause hair loss, but that hair usually grows back after treatment ends.

• Advise female patient to use barrier contraception during therapy and for 1 month afterward.

• Advise breastfeeding women not to breastfeed while taking this drug.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

cy·clo·phos·pha·mide (CTX),

(sī'klō-fos'fă-mīd), An alkylating agent with antitumor activity and uses similar to those of its parent compound, nitrogen mustard (mechlorethamine hydrochloride); also a suppressor of B-cell activity and antibody formation.

cyclophosphamide

(sī′klə-fŏs′fə-mīd′)n. A cytotoxic, immunosuppressive, antineoplastic drug, C₇H₁₅Cl₂N₂O₂P, used in the treatment of Hodgkin and non-Hodgkin lymphomas and various other forms of cancer, including multiple myeloma, breast cancer, and certain types of leukemia.

cyclophosphamide

Cytoxan^®, Neosar^® Oncology An alkylating chemotherapeutic used for lymphomas, CAs, and for immunosuppression in nephrotic syndrome Adverse effects BM suppression, cystitis, alopecia, N&V Contraindications Hypersensitivity, marked thrombocytopenia, leukopenia, hemorrhagic cystitis, lung toxicity related to previous therapy with an alkylating agent

cy·clo·phos·pha·mide

(sī'klō-fos'fă-mīd) An alkylating agent with antitumor activity and uses similar to those of its parent compound, nitrogen mustard (mechlorethamine hydrochloride); also a suppressor of B-cell activity and antibody formation.

cyclophosphamide

A drug that substitutes an open chain hydrocarbon radical for a hydrogen atom in a cyclic organic compound. It is an alkylating agent and is used as an anticancer drug for its alkylating action on the guanine molecule in DNA. The margin between the effective dose and the dangerous dose is narrow. Side effects include loss of hair, sterility, sickness and vomiting and depression of blood formation by the bone marrow. The drug is on the WHO official list. A brand name is Endoxana.

immunosuppressants

Drugs that prevent or reduce the immune response. They are used in the treatment of a variety of severe inflammations such as uveitis, scleritis, keratoconjunctivitis sicca, Behçet's syndrome, sympathetic ophthalmia, and to prevent corneal graft rejection. They include the corticosteroids (e.g. prednisolone), ciclosporin (cyclosporine), tacrolimus, and cytotoxic agents (e.g. azathioprine, chlorambucil, cyclophosphamide, methotrexate). It must be noted that immunosuppressants render the patient more susceptible to infection because immunity is reduced.

cy·clo·phos·pha·mide

(sī'klō-fos'fă-mīd) Alkylating agent with antitumor activity and uses similar to those of its parent compound, nitrogen mustard.

单词	cyclophosphamide
释义	cyclophosphamide enUK cy·clo·phos·pha·mide C0836500 (sī′klə-fŏs′fə-mīd′)n. A cytotoxic, immunosuppressive, antineoplastic drug, C₇H₁₅Cl₂N₂O₂P, used in the treatment of Hodgkin and non-Hodgkin lymphomas and various other forms of cancer, including multiple myeloma, breast cancer, and certain types of leukemia. cyclophosphamide (ˌsaɪkləʊˈfɒsfəˌmaɪd) n (Pharmacology) an alkylating agent used in the treatment of leukaemia and lymphomas[C20: from cyclo- + phosph(orus) + amide] Translations EncyclopediaSeeCytoxan cyclophosphamide enUK cyclophosphamide [si″klo-fos´fah-mīd] a cytotoxic alkylating agent, one of the nitrogen mustards, used in antineoplastic therapy for a wide variety of conditions, often in combination with other agents; also used as an immunosuppressant to prevent transplant rejection and in the treatment of certain diseases with abnormal immune function. cyclophosphamide Endoxana (UK), Procytox (CA) *Pharmacologic class: Alkylating agent, nitrogen mustard Therapeutic class: Antineoplastic Pregnancy risk category D* Action Unclear. Thought to prevent cell division by cross-linking DNA strands, thereby interfering with growth of susceptible cancer cells. Availability Powder for injection: 500 mg, 1 g, 2 g Tablets: 25 mg, 50 mg Indications and dosages ➣ Hodgkin's disease; malignant lymphoma; multiple myeloma; leukemia; advanced mycosis fungoides; neuroblastoma; ovarian cancer; breast cancer; and certain other tumors Adults: Initially, 40 to 50 mg/kg I.V. in divided doses over 2 to 5 days, or 10 to 15 mg/kg I.V. q 10 days, or 3 to 5 mg/kg I.V. twice weekly. Children: Initially, 2 to 8 mg/kg or 60 to 250 mg/m² P.O. or I.V. daily in divided doses for 6 or more days. Maintenance dosage is 2 to 5 mg/kg or 50 to 150 mg/m² P.O. twice weekly. ➣ Biopsy-proven nephrotic syndrome in children Children: 2.5 to 3 mg/kg/day P.O. for 60 to 90 days Off-label uses • Severe rheumatologic conditions • Selected cases of severe progressive rheumatoid arthritis and systemic lupus erythematosus Contraindications • Hypersensitivity to drug • Severe bone marrow depression Precautions Use cautiously in: • renal or hepatic impairment, adrenalectomy, mild to moderate bone marrow depression, other chronic debilitating illnesses • females of childbearing age • pregnant patients • breastfeeding patients (use not recommended). Administration • Verify that patient isn't pregnant before administering. • Follow facility procedures for safe handling, administration, and disposal of chemotherapeutic drugs. • Administer tablets on empty stomach. If drug causes severe GI upset, give with food. • Don't cut or crush tablets. • Know that dosage may need to be decreased if drug is given with other antineoplastics. • Dilute each 100 mg of powder with 5 ml of sterile water for injection, to yield 20 mg/ml. Further dilute with compatible fluid, such as 5% dextrose injection, 5% dextrose and normal saline solution for injection, 5% dextrose and Ringer's injection, lactated Ringer's injection, or half-normal saline solution for injection. • For I.V. injection, give each 100 mg over at least 1 minute. When giving dosages above 500 mg diluted in 100 to 250 ml of compatible solution, administer over 20 to 60 minutes. • Use solution prepared with bacteriostatic water for injection within 24 hours if stored at room temperature or within 6 days if refrigerated. • To minimize bladder toxicity, increase patient's fluid intake during therapy and for 1 to 2 days afterward. Most adults require fluid intake of at least 2 L/day. Adverse reactions CV: cardiotoxicity GI: nausea, vomiting, diarrhea, abdominal pain or discomfort, stomatitis, oral mucosal ulcers, anorexia, hemorrhagic colitis GU: urinary bladder fibrosis, hematuria, amenorrhea, decreased sperm count, sterility, acute hemorrhagic cystitis, renal tubular necrosis, hemorrhagic ureteral inflammation Hematologic: anemia, leukopenia, thrombocytopenia, bone marrow depression, neutropenia Hepatic: jaundice Metabolic: hyperuricemia Respiratory: interstitial pulmonary fibrosis Skin: nail and pigmentation changes, alopecia Other: poor wound healing, infections, allergic reactions including anaphylaxis, secondary cancer Interactions Drug-drug. Allopurinol, thiazide diuretics: increased risk of leukopenia Digoxin: decreased digoxin blood level Cardiotoxic drugs (such as cytarabine, daunorubicin, doxorubicin): additive cardiotoxicity Chloramphenicol: prolonged cyclophosphamide half-life Phenobarbital: increased risk of cyclophosphamide toxicity Quinolones: decreased antimicrobial effect Succinylcholine: prolonged neuromuscular blockade Warfarin: increased anticoagulant effect Drug-diagnostic tests. Hemoglobin, platelets, pseudocholinesterase, red blood cells (RBCs), white blood cells: decreased values Uric acid: increased level Patient monitoring • Assess infusion site for signs of extravasation. • Monitor hematologic profile to determine degree of hematopoietic suppression. Be aware that leukopenia is an expected drug effect and is used to help determine dosage. • Monitor urine regularly for RBCs, which may precede hemorrhagic cystitis. Patient teaching • Tell patient to take tablets on empty stomach. However, if GI upset occurs, instruct him to take them with food. See Advise patient to promptly report unusual bleeding or bruising, fever, chills, sore throat, cough, shortness of breath, seizures, lack of menstrual flow, unusual lumps or masses, flank or stomach pain, joint pain, mouth or lip sores, or yellowing of skin or eyes. • Instruct patient to drink 2 to 3 L of fluids daily (unless prescriber has told him to restrict fluids). • Tell patient that drug may cause hair loss, but that hair usually grows back after treatment ends. • Advise female patient to use barrier contraception during therapy and for 1 month afterward. • Advise breastfeeding women not to breastfeed while taking this drug. • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above. cy·clo·phos·pha·mide (CTX), (sī'klō-fos'fă-mīd), An alkylating agent with antitumor activity and uses similar to those of its parent compound, nitrogen mustard (mechlorethamine hydrochloride); also a suppressor of B-cell activity and antibody formation. cyclophosphamide (sī′klə-fŏs′fə-mīd′)n. A cytotoxic, immunosuppressive, antineoplastic drug, C₇H₁₅Cl₂N₂O₂P, used in the treatment of Hodgkin and non-Hodgkin lymphomas and various other forms of cancer, including multiple myeloma, breast cancer, and certain types of leukemia. cyclophosphamide Cytoxan^®, Neosar^® Oncology An alkylating chemotherapeutic used for lymphomas, CAs, and for immunosuppression in nephrotic syndrome Adverse effects BM suppression, cystitis, alopecia, N&V Contraindications Hypersensitivity, marked thrombocytopenia, leukopenia, hemorrhagic cystitis, lung toxicity related to previous therapy with an alkylating agent cy·clo·phos·pha·mide (sī'klō-fos'fă-mīd) An alkylating agent with antitumor activity and uses similar to those of its parent compound, nitrogen mustard (mechlorethamine hydrochloride); also a suppressor of B-cell activity and antibody formation. cyclophosphamide A drug that substitutes an open chain hydrocarbon radical for a hydrogen atom in a cyclic organic compound. It is an alkylating agent and is used as an anticancer drug for its alkylating action on the guanine molecule in DNA. The margin between the effective dose and the dangerous dose is narrow. Side effects include loss of hair, sterility, sickness and vomiting and depression of blood formation by the bone marrow. The drug is on the WHO official list. A brand name is Endoxana. immunosuppressants Drugs that prevent or reduce the immune response. They are used in the treatment of a variety of severe inflammations such as uveitis, scleritis, keratoconjunctivitis sicca, Behçet's syndrome, sympathetic ophthalmia, and to prevent corneal graft rejection. They include the corticosteroids (e.g. prednisolone), ciclosporin (cyclosporine), tacrolimus, and cytotoxic agents (e.g. azathioprine, chlorambucil, cyclophosphamide, methotrexate). It must be noted that immunosuppressants render the patient more susceptible to infection because immunity is reduced. cy·clo·phos·pha·mide (sī'klō-fos'fă-mīd) Alkylating agent with antitumor activity and uses similar to those of its parent compound, nitrogen mustard. AcronymsSeecontext
随便看	alternative service processing system alternative service provider alternative service worker alternatives for community and environment alternatives for youth alternative sheltered employment alternatives in publication alternative site processing team alternative site provider alternative small target block alternative society alternatives of benefits and cost alternative solution for international accounting alternative-south texas educator program alternative space craft alternative specific constants alternative splicing alternative splicing factor alternative splicing of the p53 mrna alternative splicings alternative sports world cup alternatives to abortion international alternatives to animal use committee alternatives to combat child labor through education and sustainable services alternatives to compressor cooling